FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288069792> ?p ?o ?g. }

• W4288069792 endingPage "103158" @default.
• W4288069792 startingPage "103158" @default.
• W4288069792 abstract "Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients.Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Data sources were Pubmed, Embase, Cochrane Library, hand search, congress abstracts, and reference lists of studies, without language restrictions. Risk estimates were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the Mantel-Haenszel method (random effects).Of 1860 identified records obtained between 1991 and 2021, 35 published studies (10 cohorts, 7 case-control, 18 cross-sectional) met inclusion criteria, including 3035 SLE patients according to American College of Rheumatology criteria and 454 cases of microvascular renal lesions. Frequency of microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 31.3% vs. 10.4%, respectively. The overall pooled odds ratios (OR) for microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 3.03 (95% confidence interval [CI], 2.25-4.09). The risk of microvascular renal lesions was the highest for lupus anticoagulant (OR = 4.84 [95% CI, 2.93 to 8.02]) and IgG anticardiolipin antibodies (OR = 3.12 [95% CI,1.08-9.02]) while the association with anti-β2-glycoprotein I antibodies (OR = 1.88 [95% CI, 0.25-14.14]) did not reach statistical significance. Furthermore, aPL were not associated with any classes of lupus nephritis.In SLE patients, aPL-positivity is associated with a significant 3- to 5-fold increased risk for specific microvascular renal lesions. This risk is mainly driven by lupus anticoagulant and IgG anticardiolipin antibodies. Our results support the inclusion of microvascular renal lesions as new criteria for definite antiphospholipid syndrome." @default.
• W4288069792 created "2022-07-28" @default.
• W4288069792 creator A5002166266 @default.
• W4288069792 creator A5002988007 @default.
• W4288069792 creator A5019135832 @default.
• W4288069792 creator A5023395186 @default.
• W4288069792 creator A5035811522 @default.
• W4288069792 creator A5037322537 @default.
• W4288069792 creator A5052193063 @default.
• W4288069792 creator A5060417778 @default.
• W4288069792 creator A5071939353 @default.
• W4288069792 creator A5074072891 @default.
• W4288069792 date "2022-10-01" @default.
• W4288069792 modified "2023-10-09" @default.
• W4288069792 title "Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis" @default.
• W4288069792 cites W1575303134 @default.
• W4288069792 cites W1975534632 @default.
• W4288069792 cites W1987670691 @default.
• W4288069792 cites W2004632147 @default.
• W4288069792 cites W2018531592 @default.
• W4288069792 cites W2023819376 @default.
• W4288069792 cites W2024596003 @default.
• W4288069792 cites W2027077460 @default.
• W4288069792 cites W2027601196 @default.
• W4288069792 cites W2034686952 @default.
• W4288069792 cites W2039346587 @default.
• W4288069792 cites W2049040665 @default.
• W4288069792 cites W2054330426 @default.
• W4288069792 cites W2054736783 @default.
• W4288069792 cites W2060509574 @default.
• W4288069792 cites W2065959087 @default.
• W4288069792 cites W2070954196 @default.
• W4288069792 cites W2075889039 @default.
• W4288069792 cites W2077266864 @default.
• W4288069792 cites W2082419907 @default.
• W4288069792 cites W2091442875 @default.
• W4288069792 cites W2092285841 @default.
• W4288069792 cites W2100652727 @default.
• W4288069792 cites W2120492526 @default.
• W4288069792 cites W2125218019 @default.
• W4288069792 cites W2125487206 @default.
• W4288069792 cites W2130604889 @default.
• W4288069792 cites W2151319957 @default.
• W4288069792 cites W2152045892 @default.
• W4288069792 cites W2152498977 @default.
• W4288069792 cites W2157721175 @default.
• W4288069792 cites W2158486964 @default.
• W4288069792 cites W2171263423 @default.
• W4288069792 cites W2253749451 @default.
• W4288069792 cites W2520489877 @default.
• W4288069792 cites W2586645760 @default.
• W4288069792 cites W2606498769 @default.
• W4288069792 cites W2623359522 @default.
• W4288069792 cites W2753653131 @default.
• W4288069792 cites W2900204727 @default.
• W4288069792 cites W3093717527 @default.
• W4288069792 cites W4211023937 @default.
• W4288069792 cites W4241121314 @default.
• W4288069792 doi "https://doi.org/10.1016/j.autrev.2022.103158" @default.
• W4288069792 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35907609" @default.
• W4288069792 hasPublicationYear "2022" @default.
• W4288069792 type Work @default.
• W4288069792 citedByCount "6" @default.
• W4288069792 countsByYear W42880697922023 @default.
• W4288069792 crossrefType "journal-article" @default.
• W4288069792 hasAuthorship W4288069792A5002166266 @default.
• W4288069792 hasAuthorship W4288069792A5002988007 @default.
• W4288069792 hasAuthorship W4288069792A5019135832 @default.
• W4288069792 hasAuthorship W4288069792A5023395186 @default.
• W4288069792 hasAuthorship W4288069792A5035811522 @default.
• W4288069792 hasAuthorship W4288069792A5037322537 @default.
• W4288069792 hasAuthorship W4288069792A5052193063 @default.
• W4288069792 hasAuthorship W4288069792A5060417778 @default.
• W4288069792 hasAuthorship W4288069792A5071939353 @default.
• W4288069792 hasAuthorship W4288069792A5074072891 @default.
• W4288069792 hasBestOaLocation W42880697921 @default.
• W4288069792 hasConcept C126322002 @default.
• W4288069792 hasConcept C156957248 @default.
• W4288069792 hasConcept C198451711 @default.
• W4288069792 hasConcept C203014093 @default.
• W4288069792 hasConcept C2776478404 @default.
• W4288069792 hasConcept C2776874634 @default.
• W4288069792 hasConcept C2779134260 @default.
• W4288069792 hasConcept C2779912601 @default.
• W4288069792 hasConcept C2780022809 @default.
• W4288069792 hasConcept C2780868729 @default.
• W4288069792 hasConcept C71924100 @default.
• W4288069792 hasConcept C90924648 @default.
• W4288069792 hasConcept C95190672 @default.
• W4288069792 hasConceptScore W4288069792C126322002 @default.
• W4288069792 hasConceptScore W4288069792C156957248 @default.
• W4288069792 hasConceptScore W4288069792C198451711 @default.
• W4288069792 hasConceptScore W4288069792C203014093 @default.
• W4288069792 hasConceptScore W4288069792C2776478404 @default.
• W4288069792 hasConceptScore W4288069792C2776874634 @default.
• W4288069792 hasConceptScore W4288069792C2779134260 @default.
• W4288069792 hasConceptScore W4288069792C2779912601 @default.
• W4288069792 hasConceptScore W4288069792C2780022809 @default.

• next